CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-22 | Ausiello Dennis A Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-06-22 | Berenson Stephen Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-06-22 | Fraser Claire Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-06-22 | Behar Gregory Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-06-22 | Graves Kurt Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-06-22 | Kender Richard N Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-06-22 | Dere Willard H Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2023-04-28 | Ege David S. | Sale | −7,038 | $5.19 | $37K | 59,696 |
| 2023-04-27 | Cloghessy Paula | Grant or award · Restricted Stock Units 10b5-1 | +18,835 | 18,835 | ||
| 2023-04-27 | Shaff Eric D. CEO and President | Grant or award · Restricted Stock Units 10b5-1 | +55,675 | 55,675 | ||
| 2023-04-27 | Young Teresa L. | Grant or award · Restricted Stock Units 10b5-1 | +22,721 | 22,721 | ||
| 2023-04-27 | Arkowitz David Chief Financial Officer | Grant or award · Restricted Stock Units 10b5-1 | +26,418 | 26,418 | ||
| 2023-04-27 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Restricted Stock Units 10b5-1 | +27,001 | 27,001 | ||
| 2023-04-27 | Ege David S. | Grant or award · Restricted Stock Units 10b5-1 | +22,721 | 22,721 | ||
| 2023-04-27 | von Moltke Lisa | Grant or award · Restricted Stock Units 10b5-1 | +27,489 | 27,489 | ||
| 2023-04-27 | Henn Matthew R. | Grant or award · Restricted Stock Units 10b5-1 | +25,245 | 25,245 | ||
| 2023-04-27 | Ege David S. | Grant or award | +20,000 | 66,734 | ||
| 2023-04-27 | Arkowitz David Chief Financial Officer | Grant or award | +42,500 | 166,613 | ||
| 2023-04-27 | Henn Matthew R. | Grant or award · Stock Option (Right to Buy) | +35,000 | 70,000 | ||
| 2023-02-03 | Ege David S. | Grant or award · Restricted Stock Units | +47,500 | 47,500 |
Page 18 of 23 · 458 trades